SHH and medulloblastoma: This variation of SST2A expression both within SHH (known to comprise many subtypes [e.g., SHH-γ, SHH-α]) and across medulloblastoma subgroups likely reflects the biological intra- and inter-tumoral heterogeneity of this disease (59, 60), for which the emerging oncogenic role of somatostatin receptor pathways warrants continued research.